Last reviewed · How we verify

NCT04320199

Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease

Recruiting now NA Last updated 4 June 2025
What this trial tests

NA trial testing Fermented Protaetia brevitarsis seulensis powder group in Alcoholic Liver Disease in 30 participants. Currently enrolling.

Timeline
1 January 2020
Primary endpoint
30 December 2025
31 December 2025

Quick facts

Lead sponsorPusan National University Yangsan Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment30
Start date1 January 2020
Primary completion30 December 2025
Estimated completion31 December 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Pusan National University Yangsan Hospital

Who can join

19 and older, any sex, with Alcoholic Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Fermented Protaetia brevitarsis seulensis powder on Alcohol-induced Liver Disease in adults for 8 weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants.
    Sharma P, Nandave M, Nandave D, Yadav S, et al · · 2023 · cited 20× · PMID 38074830

Verify or expand the search:

Other recruiting trials for Alcoholic Liver Disease

Currently open trials in the same condition.

Other Pusan National University Yangsan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing